Loading...
Loading...
Array BioPharma Inc.
announced positive data for newly named filanesib (ARRY-520) as a single
agent and in combination with proteasome inhibitors (PI) in patients with
multiple myeloma (MM) at the 2013 Annual Meeting of the American Society of
Hematology.
Filanesib is a highly selective, targeted KSP inhibitor with a mechanism of
action distinct from currently available drugs to treat MM such as
immunomodulatory drugs (IMiD) and PIs. Across multiple studies, filanesib has
demonstrated activity in heavily pre-treated MM patients, with a consistent
safety profile including no drug-induced peripheral neuropathy and limited
non‑hematologic toxicity. Adverse events are generally limited to transient,
non-cumulative and predominantly asymptomatic hematologic effects.
"Filanesib has shown clinical activity in relapsed/refractory multiple myeloma
patients, both as a single agent, and in separate combination trials with
Kyprolis and Velcade," said Jatin J. Shah, M.D., Assistant Professor,
Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas, MD
Anderson Cancer Center. "These results support advancing filanesib into
pivotal trials to confirm the promising activity we've seen to date."
"Multiple myeloma remains an incurable disease, with a significant unmet
medical need in patients who are relapsed/refractory to IMiDs and proteasome
inhibitors," said Michael Needle, M.D., Chief Medical Officer, Array
BioPharma. "Filanesib is a first-in class drug in myeloma that is well
tolerated and has shown very encouraging clinical activity in heavily
pretreated patients who have limited therapeutic options. Furthermore, we are
excited about the potential of our patient selection marker, AAG, which should
help us identify which patients have the best chance to benefit from receiving
filanesib."
Below are highlights of each presentation. The posters and presentation
slides are available as PDFs on Array's website at www.arraybiopharma.com.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in